Barbara Romanowski

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Jorma Paavonen, Paulo Naud, Jorge Salmerón et al. · The Lancet · 2009 · 1.6K citations

As04-adjuvanted Vaccine, Gynecology, Oncogenic Hpv Types +16

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2006 · 1.6K citations · Full text

Vaccination, Vaccinology, Vaccine Development +8

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Matti Lehtinen, Jorma Paavonen, Cosette M. Wheeler et al. · The Lancet Oncology · 2011 · 693 citations

Vaccination, Cervical Cancer Screening, Hpv-16/18 As04-adjuvanted Vaccine +14

Hospital-acquired Infection with Vancomycin-resistant <i>Enterococcus faecium</i> Transmitted by Electronic Thermometers

Lawrence L. Livornese, Susan Dias, Carol Samel et al. · Annals of Internal Medicine · 1992 · 503 citations

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Cosette M. Wheeler, Xavier Castellsagué, Suzanne M. Garland et al. · The Lancet Oncology · 2011 · 499 citations

Vaccination, Vaccine Safety, Cervical Cancer Screening +14